HEAL THE WORLD

A New Light in Cancer Care

Healing Without Harm.

For too long, the journey through cancer treatment has been defined by a difficult compromise: accepting harsh, often debilitating side effects such as hair loss, perpetual fatigue and constant pain in the pursuit of a cure. Patients have been asked to endure not just the disease, but the trauma brought on by it’s treatment.

At Quercis, we believe there is a better way. Our lead therapy is engineered to precisely target a life-threatening complication of cancer without causing systemic harm, resolving the historic conflict between a drug's power and a patient's quality of life. We are trying to create a future where healing is a restorative process, not a destructive one.

0x
0x

Increased mortality for cancer patients who develop a VTE.

2nd

Leading cause of death in many cancers, after the cancer itself.

0x
0x

Of all cancer-related deaths are attributable to VTE.

The Unseen Risk in Cancer Care

For patients fighting cancer, the battle is often compounded by a silent but deadly threat: venous thromboembolism (VTE), or blood clots.

OUR SCIENCE

Data-Driven Solutions, Designed for Life.

Our innovation begins with the elegant wisdom of nature. The flavonoid at the heart of our platform is a highly purified, naturally derived compound, providing a powerful and proven foundation for our science. But our work doesn't stop there. Through rigorous pharmacology and data-driven development, we transform this natural potential into precision-engineered medicine, creating therapies that are both intelligent and human.

KINISOQUIN

Precision, Protection, and Peace of Mind.

Our lead candidate, Kinisoquin™, represents a new orbit of therapy. It is a novel, proprietary formulation designed to inhibit Protein Disulfide Isomerase (PDI), a key enzyme that initiates the dangerous cascade of thrombo-inflammation.

Unlike traditional anticoagulants, its action is precise and localized. It selectively blocks PDI release from endothelial cells and platelets, preventing clots from forming without systemically altering the body's essential coagulation functions. This targeted approach is the key to its exceptional safety profile.

"Developing an effective and safe antithrombotic agent would greatly improve adoption of primary prevention strategies in the cancer community. The primary concern with currently available anticoagulants is the increased risk of hemorrhage."

Jeffrey Zwicker, MD

Professor of Medicine, Memorial Sloan Kettering Cancer Center (MSK)


LEARN MORE

OUR PARTNERS

Data-Driven Solutions, Designed for Life.

OUR MISSION

Broad Applications, One Healing Goal.

Our journey begins with one of the most urgent needs in oncology: preventing life-threatening thrombosis in cancer patients. But the potential of our platform is far greater. We have seen anti-neoplastic effects that could treat the tumors and we hope this can be confirmed in ongoing Clinical Trials in humans. With promising applications in Sickle Cell Disease, Amyotrophic Lateral Sclerosis (ALS), and other complex conditions, we are pursuing a broad pipeline guided by a singular mission: to bring our transformative science to every patient we can possibly help.

Oncology & Thrombosis

Rare & Blood Disorders

Neurological & Viral

Lead Indication: Cancer-Associated Thrombosis

Prevention of VTE in high-risk solid tumors. With a clear regulatory path forward via a FDA Special Protocol Agreement (SPA), our Phase 3 program if successful will deliver a new best in class standard of care.

Anti-Neoplastic Effects

Initial data suggests our PDI inhibitors may have direct anti-cancer properties. We are actively investigating this potential to which has shown tumor size reduction both using our PDI inhibitors alone as well as together with existing chemotherapy agents and repurposed off-patent drugs newly patented together with our PDI inhibitors to fight cancer on multiple fronts.

Oncology & Thrombosis

Rare & Blood Disorders

Neurological & Viral

Lead Indication: Cancer-Associated Thrombosis

Prevention of VTE in high-risk solid tumors. With a clear regulatory path forward via a FDA Special Protocol Agreement (SPA), our Phase 3 program if successful will deliver a new best in class standard of care.

Anti-Neoplastic Effects

Initial data suggests our PDI inhibitors may have direct anti-cancer properties. We are actively investigating this potential to which has shown tumor size reduction both using our PDI inhibitors alone as well as together with existing chemotherapy agents and repurposed off-patent drugs newly patented together with our PDI inhibitors to fight cancer on multiple fronts.

OUR TEAM

A World-Class Team for a Global Mission.

Executing a mission of this scale requires leadership with deep experience, global perspective, and unwavering dedication.

Leadership

Thomas Lines D.Sc (h.c.)

Chief Executive Officer

Yves Grumser MD

Chief Medical Officer


Richard O'Neil JD

Chief Operating Officer

Gerhard Ries, Ph.D

Senior Business Advisor

Natalia Seipel Nikolic, JD

Global Manager: Corporate and Business Development

Harry Welten

Chief Financial Officer

Stefan Wohlfeil, MD

Senior Medical Advisor

Daniel Drexler, MD

President, North America

Scientific Advisory Board

Our strategy is informed and validated by global leaders in oncology, hematology, and neurodegenerative disease.

Prof. Dr. Jean Pierre Bizzari

Former CMO of Cellgene, Chairman of EORTC New Drug Advisory Committee

Prof. Dr. Manuel Hildalgo

Chief of the Division of Hematology and Medical Oncology at the Weill Department of Medicine, Cornell University

Prof. Dr. Louis Barbeito

Former Head Laboratory of Neurodegeneration at Pasteur Institute in Uruguay

Prof. Dr. Jean-Pierre Kinet

Immunologist and Professor Emeritus at Harvard Medical School

Prof. Dr. Simone Schürle-Finke

Head of Responsive Biomedical System Lab at ETH, Zurich

VIEW FULL TEAM

CONTACT US

A World-Class Team for a Global Mission.

Executing a mission of this scale requires leadership with deep experience, global perspective, and unwavering dedication.

A New Light in Cancer Care.

KEY PUBLICATIONS

© 2025 Quercis. All rights reserved.

A New Light in Cancer Care.

KEY PUBLICATIONS

© 2025 Quercis. All rights reserved.

A New Light in Cancer Care.

KEY PUBLICATIONS

© 2025 Quercis. All rights reserved.